Patent Pool May Be a Key Factor in Open RAN Adoption, Report Says
A patent pool may play a key role in the adoption of Open RAN technology, according to a recent report published by Harvard Business School Professor Josh Lerner and Bella Private Markets.
The report entitled “Accelerating innovation in connectivity: The case for an Open RAN patent pool”, which can be found here, was commissioned by Alium, a joint venture between MPEG LA and Unified Patents. Alium launched the Open RAN Patent Portfolio License last year. See https://www.alium-llc.com/blog/alium-introduces-open-ran-patent-portfolio-license
"Patent pools have historically played a critical role in supporting innovation by reducing risks around intellectual property and encouraging investment in new technologies. One such technology is Open RAN, a key component in unlocking widespread 5G adoption,” said Professor Lerner. “The Alium pool represents one effort to accelerate the adoption of Open RAN and help realize its many potential benefits."
“We appreciate the work of Josh Lerner and Bella Private Markets demonstrating a patent pool’s role in the adoption of Open RAN technology,” said Craig Thompson, a licensing executive at Alium. “While Open RAN has the potential to reshape the market for mobile telecommunications by increasing vendor diversity, lowering costs and energy consumption, facilitating wider adoption of 5G, and giving operators greater control over their networks, it relies on a crowded and complex patent landscape with little or no royalty benchmarking information. That’s where the Alium Patent Pool comes in. Based on our experience, we are confident that Alium’s Open RAN Patent Pool will reduce royalty stacking, hold-up, and expensive litigation risks, helping Open RAN implementers save billions in costs while accelerating future revenue growth, profitability, and new service deployments.”
Alium’s objective is to offer worldwide access to as many Open RAN essential patents as possible to everyone on the same terms under a single license. Alium welcomes the participation of any party with at least one patent that is essential to the Open RAN Standard. For more information, please go to https://www.alium-llc.com/licensors.
Josh Lerner and Bella Private Markets
Bella Private Markets focuses exclusively on providing solutions to the challenges facing the private capital industry. Led by Harvard Business School Professor Dr. Josh Lerner, Bella combines rigorous academic approaches with real world industry expertise to provide actionable insights for its clients. Bella focuses on complex, customized projects that require thorough analysis, whether quantitative or qualitative in nature, to help its clients improve performance, optimize operations, and chart winning strategies for the future.
Alium
Alium, a joint venture between MPEG LA and Unified Patents, supports Open RAN with the first patent pool for telecommunications infrastructure. Open RAN provides network operators with greater control and flexibility in deploying 4G and next generation 5G networks, and the Alium patent pool provides a one-stop solution to the uncertainty and risk posed by as many as tens of thousands of patents owned by numerous patent owners that cover the 3GPP standardized lower physical layer functionalities performed by radio units applying the O-RAN Alliance’s 7-2x baseband architecture split.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005684/en/
Contact information
Tom O’Reilly
Alium
Tel: 303.200.1710
tom@alium-llc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
